Magia Technology and General Biology (Anhui) Co., Ltd. have officially signed a strategic cooperation agreement aimed at building an intelligent research and development system for innovative drugs. The core objective of this partnership is to develop smart R&D infrastructure tailored for innovative pharmaceuticals, leveraging each party’s technological, resource, and industrial strengths.
The collaboration will integrate AI and autonomous intelligent systems to transform the research and production processes at General Biology. Together, they aim to establish an AI-driven next-generation autonomous laboratory that will serve the life sciences research community and facilitate the digital transformation of the biopharmaceutical CRO/CDMO sector, creating a replicable and scalable benchmark model.
Currently, AI4S (AI for Science) is profoundly reshaping the foundational logic of the biopharmaceutical industry. The life sciences research services and CRO/CDMO industries are transitioning from a phase of homogeneous competition driven by scale to a new arena focused on value innovation. General Biology, as a global one-stop biotechnology service platform, has developed a controllable integrated technology platform encompassing nucleic acids, proteins, and antibodies. They have accumulated a rich technical system and extensive industry experience in key areas such as oligonucleotide synthesis, plasmid synthesis, protein expression and purification, antibody preparation, and omics services.
In parallel, Magia Technology, a pioneer and leader in the application of autonomous intelligent systems, has created an intelligent laboratory system capable of realizing a closed-loop iteration model encompassing perception, conceptualization, execution, and feedback within biopharmaceutical R&D. The company has validated practical experience in the “black box laboratory” approach.
Through this collaboration, Magia will focus on multi-agent cluster technology to enhance and integrate the various technological platforms at General Biology, including oligonucleotide synthesis, plasmid synthesis and preparation, recombinant protein/antibody expression, custom antibody development, virus packaging, and sequencing services. This initiative will seamlessly incorporate AI throughout the entire R&D process, from experimental design to result analysis, achieving comprehensive upgrades in high throughput, automation, and autonomy, thereby strengthening General Biology’s smart capabilities in life sciences research and biopharmaceutical services.
This cooperative model not only significantly boosts R&D and production efficiency, reduces costs, and accelerates delivery times but also ensures the stability and reproducibility of experimental results at a foundational level. It aims to provide global clients with more efficient, precise, and predictable research services and biopharmaceutical CRO/CDMO offerings.
Yong Jingu, General Manager of General Biology, noted that “biopharmaceutical innovation has entered a new competitive landscape globally, and the life sciences research service and biopharmaceutical CRO/CDMO sectors have also entered a new stage of technology-driven value innovation. General Biology’s industrial foundation in processes and quality is highly complementary to Magia Technology’s intelligent technology. This strategic cooperation marks an important integration of biological manufacturing and intelligent technology. We will leverage Magia’s multi-agent cluster technology to drive the automation and intelligent upgrades of our entire production chain, significantly enhancing R&D and production efficiency and achieving a leap in capacity across our technology platforms and business segments.”
Zhang Yan, Co-founder and Senior Vice President of Magia Technology, expressed that “the life sciences research services and biopharmaceutical CRO/CDMO industries are transitioning from traditional resource expansion to a new phase of high-quality development driven by technology and value innovation. General Biology has a solid foundational platform and real R&D scenarios in the nucleic acid-protein-antibody domain, which is the ideal environment for the autonomous intelligent technology to deliver value. Magia’s core capability is not just to provide automated tools but to create a technological architecture that allows AI to ‘grow and evolve’ in real experimental settings. We look forward to collaborating closely with General Biology to make AI a core force in new drug development, enabling it to perceive, think, and make decisions, thereby jointly promoting high-quality development in the biopharmaceutical industry.”
Original article by NenPower, If reposted, please credit the source: https://nenpower.com/blog/magia-technology-and-general-biology-form-strategic-partnership-to-create-intelligent-drug-development-system/
